Leflunomide: A possible alternative for gangciclovir sensitive and resistant cytomegalovirus infections

Postgraduate Medical Journal

Volumn 82, Issue 967, 2006, Pages 313-314

  Sudarsanam, T D ^a   Sahni, R D ^a   John, G T ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; LEFLUNOMIDE; TERIFLUNOMIDE;

ANEMIA; ANTIBIOTIC RESISTANCE; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DEVELOPING COUNTRY; DOSE RESPONSE; DRUG COST; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; LEUKOPENIA; LIVER FAILURE; LIVER TOXICITY; NONHUMAN; PHYSICIAN; PROPHYLAXIS; REVIEW; TERATOGENICITY; TREATMENT DURATION; VIRION;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; GANCICLOVIR; HUMANS; ISOXAZOLES; RATS;

EID: 33646858091     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2005.038521     Document Type: Review

References (12)

1. Patel R, Surydman DR, Rubin RH, et al. Cytomegalovirus prophylaxes in solid organ transplant recipients. Transplantation 1999;61:1279-89.
2. Crumpacker CS. Gangciclovir. N Engl J Med 1996;355:721-9.
3. Erice A, Chou S, Biron KK, et al. Progressive disease due to gangciclovir-resistance Cytomegalovirus in immunocompromised patients. N Engl J Med 1989;320:289-93.
4. Jacobson MA, Wullfsohn M, Feinburg JE, et al. Phase II dose ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant or resistant to gangciclovir (ACTG protocol 093). AIDS 1994;8:451-9.
5. Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous gangciclovir for peripheral cytomegalovirus retinitis patients with AIDS. A randomised, controlled trial. Ann Intern Med 1997;126:257-63.
6. Waldman WJ, Knight DA, Blinder L, et al. Inhibition of cytomegalovirus in vitro and in vivo by the experimental. Immunosuppressive agent leflunomide. Intervirology 1999;42:412-18.
7. Waldman WJ, Knight DA, Lurain NS, et al. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation 1999;68:814-25.
8. John GT, Manivannan J, Chandy S, et al. Leflunomide therapy for cytomegalovirus disease in renal allograft recepients. Transplantation 2004;77:1460-1.
9. Avery RK, Bolwell BJ, Yen-Lieberman B, et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 2004;34:1071-5.
10. Evers DL, Wang X, Huong SM, et al. Inhibition of human cytomegalovirus signaling and replication by the immunosuppressant FK778. Antiviral Res 2005;65:1-12.
11. Zeng H, Waldman WJ, Yin DP, et al. Mechanistic study of malononitrileamide FK778 in cardiac transplantation and CMV infection in rats. Transplantation 2005;15:17-22.
12. Trofe J, Gordon J, Roy-Chaudhury P, et al. Basic and clinical research in polyomavirus nephropathy. Exp Clin Transplant 2004;2:162-73.